New cancer drug combo targets tough tumors in early trial
NCT ID NCT07158918
Summary
This early-stage trial is testing a new drug called ABL103, given alongside an existing immunotherapy (pembrolizumab) and sometimes with chemotherapy. It aims to see if this combination is safe and can help control advanced solid tumors that have stopped responding to standard treatments. The study will enroll about 65 adults whose cancer has spread or cannot be surgically removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
NOT_YET_RECRUITINGSeoul, 05505, South Korea
-
PASO Medical
NOT_YET_RECRUITINGFrankston, Victoria, 3199, Australia
-
Samsung Medical Center
NOT_YET_RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam, 13620, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
UH Cleveland Medical Center
NOT_YET_RECRUITINGCleveland, Ohio, 44106, United States
Conditions
Explore the condition pages connected to this study.